Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine

Vaccine

Volumn 34, Issue 50, 2016, Pages 6426-6435

  Coudeville, Laurent ^a   Baurin, Nicolas ^a   L'Azou, Maïna ^a   Guy, Bruno ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Dengue; Dengue vaccines; Epidemiology; Prevention control

Indexed keywords

DENGUE VACCINE;

ARTICLE; BRAZIL; CHILD; COLOMBIA; DENGUE; DRUG EFFICACY; HEALTH IMPACT ASSESSMENT; HEALTH PROGRAM; HONDURAS; HUMAN; INDONESIA; INFECTION CONTROL; INFECTION PREVENTION; MALAYSIA; MATHEMATICAL MODEL; MEXICO; PHASE 3 CLINICAL TRIAL (TOPIC); PHILIPPINES; PRIORITY JOURNAL; PUERTO RICO; SEROTYPE; THAILAND; VACCINATION; VIET NAM; VIRUS TRANSMISSION; ADOLESCENT; ADULT; AGED; ASIA; DISEASE TRANSMISSION; FEMALE; IMMUNOLOGY; INFANT; MALE; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PREVENTION AND CONTROL; SOUTH AND CENTRAL AMERICA; TRANSMISSION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE III AS TOPIC; DENGUE; DENGUE VACCINES; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LATIN AMERICA; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84995390396     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.08.050     Document Type: Article

References (46)

1. [1] Brady, O.J., Gething, P.W., Bhatt, S., Messina, J.P., Brownstein, J.S., Hoen, A.G., et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis, 6, 2012, e1760.
2. [2] Dick, O.B., San Martín, J.L., Montoya, R.H., del Diego, J., Zambrano, B., Dayan, G.H., The history of dengue outbreaks in the Americas. Am J Trop Med Hyg 87 (2012), 584–593.
3. [3] San Martin, J.L., Brathwaite, O., Zambrano, B., Solorzano, J.O., Bouckenooghe, A., Dayan, G.H., et al. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg 82 (2010), 128–135.
4. [4] World Health Organization, Dengue and dengue haemorrhagic fever, Fact sheet Nø117. , 2015.
5. [5] L'Azou M, Brett J, Marsh G, Sarti E. Reviewing the Literature for Epidemiological Trends of Dengue Disease: Introduction to a Series of Seven National Systematic Literature Reviews; 2014.
6. [6] Messina, J.P., Brady, O.J., Scott, T.W., Zou, C., Pigott, D.M., Duda, K.A., et al. Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol 22 (2014), 138–146.
7. [7] World Health Organization, Global strategy for dengue prevention and control: 2012-2020. Available from: , 2012 [accessed 7 July 2014].
8. [8] Villar, L., Dayan, G.H., Arredondo-Garcia, J.L., Rivera, D.M., Cunha, R., Deseda, C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med, 2014.
9. [9] Capeding, M.R., Tran, N.H., Hadinegoro, S.R., Ismail, H.I., Chotpitayasunondh, T., Chua, M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384 (2014), 1358–1365.
10. [10] Hadinegoro, S.R., Arredondo-García, J.L., Capeding, M.R., Deseda, C., Chotpitayasunondh, T., Dietze, R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373 (2015), 1195–1206.
11. [11] Group W-VDVM, Assessing the potential of a candidate dengue vaccine with mathematical modeling. PLoS Negl Trop Dis, 6, 2012.
12. [12] Coudeville, L., Garnett, G.P., Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination. PLoS ONE, 7, 2012, e51244.
13. [13] Chao, D.L., Halstead, S.B., Halloran, M.E., Longini, I.M. Jr., Controlling dengue with vaccines in Thailand. PLoS Negl Trop Dis, 6, 2012, e1876.
14. [14] Rodriguez-Barraquer, I., Mier-y-Teran-Romero, L., Schwartz, I.B., Burke, D.S., Cummings, D.A., Potential opportunities and perils of imperfect dengue vaccines. Vaccine 32 (2014), 514–520.
15. [15] Thavara, U., Tawatsin, A., Nagao, Y., Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control. Epidemiol Infect 142 (2014), 1245–1258.
16. [16] Knerer, G., Currie, C.S., Brailsford, S.C., Impact of combined vector-control and vaccination strategies on transmission dynamics of dengue fever: a model-based analysis. Health Care Manage Sci, 2013.
17. [17] Ndeffo Mbah, M.L., Durham, D.P., Medlock, J., Galvani, A.P., Country- and age-specific optimal allocation of dengue vaccines. J Theor Biol 342 (2014), 15–22.
18. [18] Durham, D.P., Ndeffo Mbah, M.L., Medlock, J., Luz, P.M., Meyers, L.A., Paltiel, A.D., et al. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine 31 (2013), 3957–3961.
19. [19] Pandey, A., Medlock, J., The introduction of dengue vaccine may temporarily cause large spikes in prevalence. Epidemiol Infect 143 (2015), 1276–1286.
20. [20] Coudeville, L., Baurin, N., Vergu, E., Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine, 2015.
21. [21] Rodriguez-Barraquer, I., Mier-y-Teran-Romero, L., Burke, D.S., Cummings, D.A., Challenges in the interpretation of dengue vaccine trial results. PLoS Negl Trop Dis, 7, 2013, e2126.
22. [22] Halloran, M.E., Haber, M., Longini, I.M. Jr., Struchiner, C.J., Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 133 (1991), 323–331.
23. [23] Yoon, I.-K., Srikiatkhachorn, A., Hermann, L., Buddhari, D., Scott, T.W., Jarman, R.G., et al. Characteristics of mild dengue virus infection in Thai children. Am J Trop Med Hyg 89 (2013), 1081–1087.
24. [24] Nguyen, N.M., Kien, D.T.H., Tuan, T.V., Quyen, N.T.H., Tran, C.N., Thi, L.V., et al. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc Natl Acad Sci 110 (2013), 9072–9077.
25. [25] Carrington, L.B., Simmons, C.P., Human to mosquito transmission of dengue viruses. Front Immunol, 5, 2014.
26. [26] Anders, K.L., Le Hong Nga, N.T.V., Van Thuy, N.T., Van Ngoc, T., Tam, C.T., Tai, L.T.H., et al. Households as foci for dengue transmission in highly urban Vietnam. PLoS Negl Trop Dis, 9, 2015 e0003528-e.
27. [27] Dussart, P., Baril, L., Petit, L., Beniguel, L., Quang, L.C., Ly, S., et al. Clinical and virological study of dengue cases and the members of their households: the multinational DENFRAME Project. PLoS Negl Trop Dis, 6, 2012, e1482.
28. [28] Shepard, D.S., Undurraga, E.A., Betancourt-Cravioto, M., Guzmán, M.G., Halstead, S.B., Harris, E., et al. Approaches to refining estimates of global burden and economics of dengue. PLoS Negl Trop Dis, 8, 2014, e3306.
29. [29] Hammond, S.N., Balmaseda, A., Perez, L., Tellez, Y., Saborío, S.I., Mercado, J.C., et al. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg 73 (2005), 1063–1070.
30. [30] Tantawichien, T., Dengue fever and dengue haemorrhagic fever in adolescents and adults. Paediatrics Int Child Health 32 (2012), 22–27.
31. [31] Wichmann, O., Hongsiriwon, S., Bowonwatanuwong, C., Chotivanich, K., Sukthana, Y., Pukrittayakamee, S., Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Tropical Med Int Health 9 (2004), 1022–1029.
32. [32] Egger, J.R., Coleman, P.G., Age and clinical dengue illness. Emerg Infect Dis 13 (2007), 924–925.
33. [33] Thai, K.T., Nishiura, H., Hoang, P.L., Tran, N.T.T., Phan, G.T., Le, H.Q., et al. Age-specificity of clinical dengue during primary and secondary infections. PLoS Negl Trop Dis, 5, 2011, e1180.
34. [34] Guy, B., Jackson, N., Dengue vaccine: hypotheses to explain the results of recent pivotal Phase III efficacy trials. Nat Rev Microbiol 14 (2016), 45–54.
35. [35] Olivera-Botello, G., Coudeville, L., Fanouillere, K., Guy, B., Chambonneau, L., Noriega, F., et al. Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue infections in healthy children and adolescents aged 2–16 years in Asia and Latin America. J Infect Dis, 2016.
36. [36] México aprueba la primera vacuna contra el virus del dengue a nivel mundial. 09/12/2015 ed.
37. [37] Halloran, M.E., Struchiner, C.J., Longini, I.M., Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 146 (1997), 789–803.
38. [38] Taranger, J., Trollfors, B., Bergfors, E., Knutsson, N., Sundh, V., Lagergård, T., et al. Mass vaccination of children with pertussis toxoid—decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 33 (2001), 1004–1009.
39. [39] Sur, D., Ochiai, R.L., Bhattacharya, S.K., Ganguly, N.K., Ali, M., Manna, B., et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 361 (2009), 335–344.
40. [40] Ali, M., Emch, M., von Seidlein, L., Yunus, M., Sack, D.A., Rao, M., et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. The Lancet 366 (2005), 44–49.
41. [41] Domı́nguez, À, Salleras, Ls, Carmona, G., Batalla, J., Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine 21 (2003), 698–701.
42. [42] Marin, M., Watson, T.L., Chaves, S.S., Civen, R., Watson, B.M., Zhang, J.X., et al. Varicella among adults: data from an active surveillance project, 1995–2005. J Infect Dis 197 (2008), S94–S100.
43. [43] Loeb, M., Russell, M.L., Moss, L., Fonseca, K., Fox, J., Earn, D.J., et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 303 (2010), 943–950.
44. [44] Clark, H.F., Lawley, D., Mallette, L.A., DiNubile, M.J., Hodinka, R.L., Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol 16 (2009), 382–386.
45. [45] Gotuzzo, E., Yactayo, S., Córdova, E., Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 89 (2013), 434–444.
46. [46] De Angelis D, Presanis AM, Birrell PJ, Tomba GS, House T. Key challenges in infectious disease modelling using data from multiple sources; 2014.